Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INR101 PET/CT for Recurrent Prostate Cancer
NCT06922929Phase 3Not yet recruiting
- Sponsor
- Yunhe Pharmaceutical
- Start
- Apr 2025
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of INR101 in prostate cancer (PCa), sponsored by Yunhe Pharmaceutical. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
INR101
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06922929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06922929.